Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
Keyword(s):
ABSTRACTOmadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active againstStaphylococcus aureus(MIC50/MIC90, 0.12/0.25 mg/liter), including methicillin-resistantS. aureus(MRSA); streptococci (MIC50/MIC90, 0.06/0.12 mg/liter), includingStreptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci;Enterobacteriaceae, includingEscherichia coli(MIC50/MIC90, 0.5/2 mg/liter);Haemophilus influenzae(MIC50/MIC90, 1/1 mg/liter); andMoraxella catarrhalis(MIC50/MIC90, 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.
2012 ◽
Vol 56
(6)
◽
pp. 2933-2940
◽
2001 ◽
Vol 39
(4)
◽
pp. 245-250
◽
2000 ◽
Vol 44
(3)
◽
pp. 747-751
◽
1999 ◽
Vol 43
(2)
◽
pp. 385-389
◽
2016 ◽
Vol 60
(6)
◽
pp. 3419-3425
◽
2007 ◽
Vol 59
(3)
◽
pp. 309-317
◽
Keyword(s):